The best peptides for inflammation, judged by evidence, are approved drugs that target specific inflammatory diseases, not the peptides sold online. Icotrokinra, an oral peptide approved in 2026, cleared or almost cleared psoriasis in 65% of patients versus 8% on placebo,[2] while KPV, BPC-157, TB-500 and LL-37 rest mostly on animal and lab work.[6][9] No peptide is proven to calm general, everyday “inflammation” in people.
Inflammation is the body’s response to injury or infection, and long-running inflammation is part of many diseases, from psoriasis to arthritis to bowel disease. Treatment works best when it targets the cause. This guide grades the popular peptides, explains what each study showed, and covers safety. For related compounds, see the healing and recovery peptides hub.
Why “anti-inflammatory” is a slippery claim
Inflammation is not one thing. Short-term, acute inflammation after a cut or sprain is part of normal healing, and blocking it too much can slow repair. Chronic inflammation is different: it is driven by a specific disease process, such as an overactive immune pathway in psoriasis or the gut in ulcerative colitis. Effective treatments usually target one pathway in one disease.
That is why lab results can mislead. A peptide that lowers an inflammation signal in a dish of cells, or in a mouse given a chemical to inflame its colon, may do nothing measurable in a person, or may affect healing in ways nobody tested. When a product claims to reduce “inflammation” in general, ask: which disease, measured how, in which human trial?
Best peptides for inflammation: evidence at a glance
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Icotrokinra (Icotyde) | FDA-approved for this use | 65% clear or almost clear psoriasis vs 8% on placebo[2] | Approved 2026 for moderate-to-severe plaque psoriasis[1] | — |
| Tirzepatide | Human RCTs (marker, not disease) | Lowered C-reactive protein vs placebo in sleep apnea trials[4] | Approved for weight management, diabetes and sleep apnea, not inflammation | Tirzepatide |
| Thymosin beta-4 (full peptide) | Small human studies | Possible faster healing of leg ulcers; less dry-eye discomfort in 9 patients[10][11] | Not approved | TB-500 |
| LL-37 | Small human studies | Low doses sped leg-ulcer healing in 34 patients[12] | Not approved; FDA lists safety concerns[15] | LL-37 |
| BPC-157 | Animal or lab only | Three poor-quality human reports, 30 people total[9] | Not approved | BPC-157 |
| KPV | Animal or lab only | Reduced colitis in mice; no human data[5][6] | Not approved | KPV |
| TB-500 (fragment) | No evidence, marketing only | No published human studies[6] | Not approved | TB-500 |
The approved option: icotrokinra
Icotrokinra is a peptide that blocks the receptor for interleukin-23, a signal that keeps psoriasis inflammation going.[1] In the ICONIC-LEAD trial of 684 adults and teens, 65% taking 200 mg daily had clear or almost-clear skin at 16 weeks versus 8% on placebo, and adverse events were equally common in both groups.[2] FDA approved it in March 2026 for moderate-to-severe plaque psoriasis in people 12 and older weighing at least 40 kg.[1]
It is also under study for ulcerative colitis. In a phase 2b trial of 252 adults, 55% to 63% responded at 12 weeks across three doses versus 27% on placebo.[3] That use is not approved yet.
GLP-1 drugs also deserve a mention. In the SURMOUNT-OSA trials, tirzepatide significantly lowered high-sensitivity C-reactive protein, a blood marker of inflammation, along with weight and sleep apnea severity.[4] That is a change in a marker, not proof of treating an inflammatory disease.
The popular peptides, graded
KPV
KPV is a three-amino-acid piece of the hormone alpha-MSH. In lab cells it blocked a key inflammation switch called NF-kappaB, and in mice, KPV in drinking water reduced chemically induced colitis.[5] That is where the evidence stops. FDA found no human studies or human exposure data by any route.[6] FDA advisers nonetheless voted 8 to 6 in July 2026 to recommend allowing it in compounding; FDA has not acted on that vote.[7]
BPC-157
BPC-157 has many rat studies but very little human data. A 2026 systematic review found three human studies with 30 people in total: a knee-pain chart review, a bladder-pain pilot and a two-person IV safety study. All were judged poor quality, and the authors concluded it should be used only in proper clinical trials.[9] The one colitis trial, a 53-person enema study published only as a meeting abstract, showed no clear difference from placebo, and FDA found the safety information insufficient.[8] Our BPC-157 clinical trials review goes deeper.
Thymosin beta-4 and TB-500
Thymosin beta-4 is a natural 43-amino-acid peptide with wound-healing and anti-inflammatory effects in the lab. As a topical gel in 73 patients with venous leg ulcers, the 0.03% dose suggested faster healing, though this was a dose-finding study.[10] As eye drops in nine people with severe dry eye, it reduced discomfort by 35% versus the control drops.[11]
TB-500, the product sold online, is a short synthetic fragment, not the full peptide. FDA found no published human studies of TB-500 by any route.[6] Our BPC-157 vs TB-500 comparison explains the difference.
LL-37
LL-37 cuts both ways. In a 34-patient trial, topical LL-37 at the two lower doses sped healing of hard-to-heal leg ulcers, while the highest dose did no better than placebo.[12] But excess LL-37 fragments drive skin inflammation in rosacea,[13] and two-thirds of people with moderate-to-severe psoriasis have T cells that attack it.[14] FDA lists it among substances with safety concerns.[15] See our LL-37 and antimicrobial peptides in wound care guide.
Safety and quality
Approved drugs come with known side effects and manufacturing standards. Peptides sold as “research use only” do not: their identity, purity, sterility and dose are unchecked, and FDA has flagged risks such as immune reactions and impurities for several peptides.[15] For KPV, FDA found no clinical or animal safety data, so its risks are simply unknown.[6] Injecting anything unsterile can cause infections and abscesses.
Questions for your clinician
- What is causing my inflammation, and is there a diagnosis that has a proven treatment?
- Would an approved targeted therapy suit me?
- Which blood tests, such as C-reactive protein, should we track?
- If I am considering a peptide, how would we know whether it is helping or harming?
The bottom line
The best peptides for inflammation are the approved ones, prescribed for a specific disease. KPV, BPC-157, TB-500 and LL-37 are popular, but their anti-inflammatory claims come mostly from animals and cells, and the small human studies that exist are topical, early or poor quality. Related reading: BPC-157 vs GHK-Cu and the KLOW blend guide, which combines several of these peptides.
This is general information, not medical advice.
